Trial | Treatments | Patients | Method |
---|
Chatterjee, 1980 | oral hydralazine (n=-9) vs. NA (n=-9) | patients with chronic CHF | Sample size: -9/-9 Primary endpoint: FU duration: |
Franciosa, 1982 | hydralazine 200 mg daily (n=16) vs. placebo (n=16) | patients with class III and IV symptoms while they were taking digitalis and diuretics | double blind Sample size: 16/16 Primary endpoint: FU duration: 20 weeks |
Conradson , 1984 | hydralazine (n=-9) vs. placebo (n=-9) | patients with chronic congestive heart failure (NYHA class III) | Sample size: -9/-9 Primary endpoint: FU duration: 1 year |
Magorien , 1984 | hydralazine 100 mg orally every eight hours (n=-9) vs. placebo (n=-9) | patients with idiopathic dilated cardiomyopathy | double blind Sample size: -9/-9 Primary endpoint: FU duration: |